Abstracts & Posters

Oral presentations:

O1 Preclinical protein signatures of Crohn’s disease and ulcerative colitis: A nested case-control study
O2 Anti-integrin αvβ6 antibodies define a severe ulcerative colitis phenotype with a distinct serum protein profile.
O3 A new Simple Endoscopic Score for Ulcerative Colitis – the SES-UC
O4 Prognostic potential of mucosal proteins in ulcerative colitis
O5 Longitudinal Changes in the Gut Microbiota of Subjects with Inflammatory Bowel Disease- IBSEN III Study

Poster presentations:

P1 The Incidence and Disease Course of Perianal Disease in Paediatric-Onset Crohn’s Disease: A Nationwide Study
P2 Increased familial IBD risk over thirty years: Insights from two population-based IBD-cohorts in South-Eastern Norway
P3 GASTROINTESTINAL BACTERIAL INFECTIONS PREDISPOSE TO DISEASE ACTIVATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
P4 Switching to subcutaneous infliximab maintenance therapy is effective in patients with inflammatory bowel disease
P5 Switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease
P6 Peripheral blood cytokines in paediatric-onset inflammatory bowel disease – a systematic review and meta-analysis
P7 The effect of rs2910686 on ERAP2 expression in IBD and the inflammatory response in colonoids
P8 Relationships and sexuality in patients with inflammatory bowel disease – The perspective of healthcare professionals
P9 Fatigue in Swedish patients with Inflammatory bowel disease
P10 HRQoL and disability after surgical vs medical treatment in Ulcerative colitis – A systematic review
P11 Colonic keratins are upregulated in severe lesions of IBD and downregulated in microscopic colitis
P12 IntesTiny: Preclinical Evaluation of the Dynamic Biotransformation of Novel Nanomaterials for Inflammatory Bowel Disease
P13 i-Tracker Risankizumab and i-Tracker Anti-Risankizumab chemiluminescent assays for the monitoring of patients treated with Risankizumab
P14 Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models
P15 Efficacy of Biological Therapies and Small Molecules in Patients with Refractory Ulcerative Proctitis
P16 Validation of IBD diagnosis date and disease location in the Danish national registers using NorDIBD
P17 COMPARATIVE AGREEMENT ANALYSIS OF A CLASSICAL LAB-BASED ASSAY AND A MOBILE PHONE-BASED QUANTITATIVE PATIENT SELF-TEST